These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28881533)

  • 1. [Efficacy and safety of Rivaroxaban anticoagulant therapy in the treatment of atrial fibrillation cryoablation].
    Di CY; Wan Z; Lin WH
    Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(33):2591-2594. PubMed ID: 28881533
    [No Abstract]   [Full Text] [Related]  

  • 2. [Impact of different anticoagulation therapies on heparin dosage applied to atrial fibrillation patients undergoing atrial fibrillation catheter ablation].
    Yang L; Gao LJ; Yin XM; Guo BL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Aug; 47(8):602-607. PubMed ID: 31434430
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of uninterrupted rivaroxaban taken preoperatively for radiofrequency catheter ablation of atrial fibrillation compared to uninterrupted warfarin.
    Tao S; Otomo K; Ono Y; Osaka Y; Hirao T; Koura K; Manno T; Ueshima D; Shimizu S; Isobe M; Hirao K
    J Interv Card Electrophysiol; 2017 Mar; 48(2):167-175. PubMed ID: 27943112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
    Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
    Lakkireddy D; Reddy YM; Di Biase L; Vallakati A; Mansour MC; Santangeli P; Gangireddy S; Swarup V; Chalhoub F; Atkins D; Bommana S; Verma A; Sanchez JE; Burkhardt JD; Barrett CD; Baheiry S; Ruskin J; Reddy V; Natale A
    J Am Coll Cardiol; 2014 Mar; 63(10):982-8. PubMed ID: 24412445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban for Periprocedural Anticoagulation Therapy in Japanese Patients Undergoing Catheter Ablation of Paroxysmal Non-Valvular Atrial Fibrillation.
    Kawabata M; Sasaki T; Maeda S; Shirai Y; Yamauchi Y; Nitta J; Goya M; Hirao K
    Int Heart J; 2016 Dec; 57(6):712-716. PubMed ID: 27818480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Experience of Novel Oral Anticoagulants in Catheter Ablation for Atrial Fibrillation: Efficacy and Safety Comparison to Warfarin.
    Shin DG; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Pak HN
    Yonsei Med J; 2016 Mar; 57(2):342-9. PubMed ID: 26847285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety of Catheter Ablation of Atrial Fibrillation Under Uninterrupted Rivaroxaban Use.
    Silva MA; Futuro GMC; Merçon ES; Vasconcelos D; Agrizzi RS; Elias Neto J; Kuniyoshi R
    Arq Bras Cardiol; 2020 Mar; 114(3):435-442. PubMed ID: 32049156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation.
    Eitel C; Koch J; Sommer P; John S; Kircher S; Bollmann A; Arya A; Piorkowski C; Hindricks G
    Europace; 2013 Nov; 15(11):1587-93. PubMed ID: 23703362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic benefits of rivaroxaban in non-valvular atrial fibrillation patients after radiofrequency catheter ablation.
    Zhu J; Gao RJ; Liu Q; Jiang RH; Yu L; Sun YX; Zhang P; Lin JW; Ye Y; Zhang ZW; Chen SQ; Cheng H; Sheng X; Jiang CY
    J Zhejiang Univ Sci B; 2017 Nov.; 18(11):946-954. PubMed ID: 29119732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.
    Zak M; Castiblanco SA; Garg J; Palaniswamy C; Jacobs LE
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):457-64. PubMed ID: 25827857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
    Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
    Snipelisky D; Ray JC; Ung R; Duart M; Kauffman C; Kusumoto F
    J Interv Card Electrophysiol; 2014 Dec; 41(3):231-6. PubMed ID: 25380703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants.
    Yamaji H; Murakami T; Hina K; Higashiya S; Kawamura H; Murakami M; Kamikawa S; Komtasubara I; Kusachi S
    Clin Drug Investig; 2016 Oct; 36(10):837-48. PubMed ID: 27389243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymptomatic Cerebral Infarction During Catheter Ablation for Atrial Fibrillation: Comparing Uninterrupted Rivaroxaban and Warfarin (ASCERTAIN).
    Kimura T; Kashimura S; Nishiyama T; Katsumata Y; Inagawa K; Ikegami Y; Nishiyama N; Fukumoto K; Tanimoto Y; Aizawa Y; Tanimoto K; Fukuda K; Takatsuki S
    JACC Clin Electrophysiol; 2018 Dec; 4(12):1598-1609. PubMed ID: 30573125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
    Vamos M; Cappato R; Marchlinski FE; Natale A; Hohnloser SH
    Europace; 2016 Dec; 18(12):1787-1794. PubMed ID: 26797248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
    Cappato R; Marchlinski FE; Hohnloser SH; Naccarelli GV; Xiang J; Wilber DJ; Ma CS; Hess S; Wells DS; Juang G; Vijgen J; Hügl BJ; Balasubramaniam R; De Chillou C; Davies DW; Fields LE; Natale A;
    Eur Heart J; 2015 Jul; 36(28):1805-11. PubMed ID: 25975659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation.
    Nagao T; Inden Y; Yanagisawa S; Kato H; Ishikawa S; Okumura S; Mizutani Y; Ito T; Yamamoto T; Yoshida N; Hirai M; Murohara T
    Heart Rhythm; 2015 Sep; 12(9):1972-8. PubMed ID: 25881495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.